UY40111A - Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas - Google Patents

Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas

Info

Publication number
UY40111A
UY40111A UY0001040111A UY40111A UY40111A UY 40111 A UY40111 A UY 40111A UY 0001040111 A UY0001040111 A UY 0001040111A UY 40111 A UY40111 A UY 40111A UY 40111 A UY40111 A UY 40111A
Authority
UY
Uruguay
Prior art keywords
helicase
crystalline forms
solid crystalline
preparation process
primase inhibitors
Prior art date
Application number
UY0001040111A
Other languages
English (en)
Spanish (es)
Inventor
Dr Gerald Kleymann Prof
Christian Gege Dr
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of UY40111A publication Critical patent/UY40111A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY0001040111A 2022-01-17 2023-01-16 Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas UY40111A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22151820 2022-01-17
EP22170332 2022-04-27

Publications (1)

Publication Number Publication Date
UY40111A true UY40111A (es) 2023-08-15

Family

ID=84982261

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040111A UY40111A (es) 2022-01-17 2023-01-16 Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas

Country Status (12)

Country Link
US (1) US20250115565A1 (cg-RX-API-DMAC10.html)
EP (1) EP4466255A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025502300A (cg-RX-API-DMAC10.html)
KR (1) KR20240134979A (cg-RX-API-DMAC10.html)
AU (1) AU2023206628A1 (cg-RX-API-DMAC10.html)
CA (1) CA3246779A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002124A1 (cg-RX-API-DMAC10.html)
IL (1) IL314188A (cg-RX-API-DMAC10.html)
MX (1) MX2024008821A (cg-RX-API-DMAC10.html)
PY (1) PY2302301A (cg-RX-API-DMAC10.html)
UY (1) UY40111A (cg-RX-API-DMAC10.html)
WO (1) WO2023135303A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4580601A1 (en) * 2022-08-29 2025-07-09 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
IL325911A (en) 2023-07-17 2026-03-01 Innovative Molecules Gmbh Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds
WO2026078039A1 (en) 2024-10-09 2026-04-16 Innovative Molecules Gmbh Oral administration forms of antiviral helicase-primase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
PH12018501979B1 (en) 2016-04-06 2023-05-05 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
PL3692039T3 (pl) 2017-10-05 2023-04-17 Innovative Molecules Gmbh Enancjomery podstawionych tiazoli jako związki przeciwwirusowe
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
AU2021367976A1 (en) 2020-10-29 2023-06-08 Innovative Molecules Gmbh Deuterated aminothiazole compounds as antiviral compounds

Also Published As

Publication number Publication date
CL2024002124A1 (es) 2024-11-22
IL314188A (en) 2024-09-01
PY2302301A (es) 2023-10-31
US20250115565A1 (en) 2025-04-10
WO2023135303A1 (en) 2023-07-20
CA3246779A1 (en) 2023-07-20
TW202337444A (zh) 2023-10-01
EP4466255A1 (en) 2024-11-27
MX2024008821A (es) 2024-07-29
KR20240134979A (ko) 2024-09-10
AU2023206628A1 (en) 2024-08-01
JP2025502300A (ja) 2025-01-24

Similar Documents

Publication Publication Date Title
PY2302301A (es) Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CL2024001964A1 (es) Compuestos para la inhibición de nlrp3 y usos de estos
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CL2023002362A1 (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
MX2021014868A (es) Oligonucleotidos y metodos de uso para el tratamiento de enfermedades neurologicas.
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2024004119A (es) Composiciones y metodos para el tratamiento de enfermedades de repeticion cag
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2025001588A1 (es) Formas cristalinas de zongertinib, un inhibidor de her2.
CO2024013531A2 (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
CR20110184A (es) Inhibidores de la integrasa del vih
MX2024010980A (es) Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor
CL2022002259A1 (es) Anticuerpos anti-axl y composiciones
CU24699B1 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
MX2024002886A (es) Metodos para tratar enfermedades neurodegenerativas.
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
CL2025000550A1 (es) Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metoxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
MX2026000476A (es) Sales clorhidrato cristalinas micronizadas de compuestos inhibidores antiviricos de la helicasa-primasa
MX2022016179A (es) Compuestos y metodos para tratar infecciones fungicas.
MX2024002887A (es) Metodos para tratar enfermedades neurodegenerativas.
CL2025000078A1 (es) Formas sólidas de un derivado de triazina como modulador cbl-b
AR121013A1 (es) Anticuerpos anti-cd40 y composiciones